ADVM Adverum Biotechnologies Inc.

6.38
+0.28  (+5%)
Previous Close 6.09
Open 6.13
Price To Book 2.31
Market Cap 410,927,604
Shares 64,459,232
Volume 2,123,967
Short Ratio
Av. Daily Volume 2,281,189
Stock charts supplied by TradingView

NewsSee all news

  1. Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting

    -- Zero anti-VEGF rescue injections required in the first cohort and durable efficacy with median follow up of 34 weeks ---- Sequential enrollment planned for OPTIC third and fourth cohorts ---- Company to host and

  2. Adverum Biotechnologies to Present Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting

    MENLO PARK, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced it

  3. Adverum Biotechnologies Reports Positive 24-Week Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD

    -- Zero anti-VEGF rescue injections required after one-time intravitreal dose of ADVM-022 -- -- Sustained improvements in retinal anatomy -- -- Was safe and well tolerated --  -- Data being presented during podium

  4. Adverum Biotechnologies to Host a Conference Call and Webcast to Present 24-week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at Retina Society 2019 Annual Meeting

    -- Podium presentation of 24-week data from first cohort of the OPTIC trial at Retina Society 2019 Annual Meeting on September 12, 2019 at 7:41 am BST -- -- Adverum to host a conference call and webcast to review

  5. Adverum Biotechnologies to Present 24-Week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October

    MENLO PARK, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Development to be discontinued - noted November 1, 2018.
ADVM-043
Alpha-1 Antitrypsin (A1AT) Deficiency
Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
AVA-101
Wet age-related macular degeneration (Wet-AMD)
Phase 1 third cohort to commence enrolment in 4Q 2019. Cohort 1 52-week data and Cohort 2 24-week data due 1H 2020.
ADVM-022
Wet age-related macular degeneration (Wet-AMD)

Latest News

  1. Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting

    -- Zero anti-VEGF rescue injections required in the first cohort and durable efficacy with median follow up of 34 weeks ---- Sequential enrollment planned for OPTIC third and fourth cohorts ---- Company to host and

  2. Adverum Biotechnologies to Present Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting

    MENLO PARK, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced it

  3. Adverum Biotechnologies Reports Positive 24-Week Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD

    -- Zero anti-VEGF rescue injections required after one-time intravitreal dose of ADVM-022 -- -- Sustained improvements in retinal anatomy -- -- Was safe and well tolerated --  -- Data being presented during podium

  4. Adverum Biotechnologies to Host a Conference Call and Webcast to Present 24-week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at Retina Society 2019 Annual Meeting

    -- Podium presentation of 24-week data from first cohort of the OPTIC trial at Retina Society 2019 Annual Meeting on September 12, 2019 at 7:41 am BST -- -- Adverum to host a conference call and webcast to review

  5. Adverum Biotechnologies to Present 24-Week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October

    MENLO PARK, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that

  6. Adverum Biotechnologies to Present 24-Week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October

    MENLO PARK, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that